Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been def...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Ryotaro, Saber, Wael, Martens, Michael J., Ramirez, Alyssa, Scott, Bart, Oran, Betul, Leifer, Eric, Tamari, Roni, Mishra, Asmita, Maziarz, Richard T., McGuirk, Joseph, Westervelt, Peter, Vasu, Sumithira, Patnaik, Mrinal, Kamble, Rammurti, Forman, Stephen J., Sekeres, Mikkael A., Appelbaum, Frederick, Mendizabal, Adam, Logan, Brent, Horowitz, Mary, Cutler, Corey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791814/
https://www.ncbi.nlm.nih.gov/pubmed/34106753
http://dx.doi.org/10.1200/JCO.20.03380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791814/
https://www.ncbi.nlm.nih.gov/pubmed/34106753
http://dx.doi.org/10.1200/JCO.20.03380

Ejemplares similares